Related Experiment Videos
Acetazolamide in the treatment of pyruvate dysmetabolism syndromes
Archives of Neurology
|May 1, 1978
Insights
Acetazolamide treatment improved pyruvate metabolism in children experiencing periodic weakness and lactic acidosis. This intervention reduced attack frequency and normalized abnormal responses to glucose loading, though its precise mechanism remains unclear.
Area of Science:
- Biochemistry
- Pediatric Neurology
- Metabolic Disorders
Background:
- Pyruvate metabolism disorders can cause significant neurological impairment in children.
- Periodic weakness and lactic acidosis indicate underlying metabolic dysfunction.
Observation:
- Two pediatric patients presented with recurrent episodes of weakness since infancy.
- Abnormal pyruvate metabolism was identified via lactic acidosis after glucose challenge.
Findings:
- Daily oral acetazolamide administration decreased the frequency of weakness episodes.
- Acetazolamide reversed the abnormal lactic acidosis response to glucose loading.
- The exact mechanism by which acetazolamide exerts its therapeutic effect is not yet understood.
Implications:
- Acetazolamide shows promise as a therapeutic agent for specific pyruvate metabolism defects.
- Further research is needed to elucidate the mechanism of action for targeted treatment development.
- Early identification and intervention in metabolic disorders are crucial for pediatric patient outcomes.
Abstract:
Two children with periodic weakness beginning in infancy were demonstrated to have abnormalities in pyruvate metabolism by the production of lactic acidosis following a glucose load. Daily oral doses of acetazolamide reduced the frequency of attacks and reversed the abnormal response to glucose loading. The mechanism of action of acetazolamide in these patients is not clear.